Equities research analysts expect Rewalk Robotics Ltd (NASDAQ:RWLK) to post sales of $1.78 million for the current quarter, Zacks reports. Two analysts have made estimates for Rewalk Robotics’ earnings, with the highest sales estimate coming in at $1.80 million and the lowest estimate coming in at $1.76 million. Rewalk Robotics posted sales of $1.59 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.9%. The firm is scheduled to announce its next quarterly earnings report on Friday, February 16th.
On average, analysts expect that Rewalk Robotics will report full-year sales of $1.78 million for the current year, with estimates ranging from $7.97 million to $8.10 million. For the next financial year, analysts expect that the company will post sales of $11.31 million per share, with estimates ranging from $11.30 million to $11.32 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Rewalk Robotics.
Rewalk Robotics (NASDAQ:RWLK) last issued its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.10. Rewalk Robotics had a negative return on equity of 568.25% and a negative net margin of 346.14%. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.63 million. During the same quarter in the prior year, the company posted ($0.62) EPS. The business’s revenue for the quarter was up 21.4% compared to the same quarter last year.
A number of brokerages have weighed in on RWLK. ValuEngine raised Rewalk Robotics from a “strong sell” rating to a “sell” rating in a research note on Friday. Canaccord Genuity restated a “buy” rating and set a $3.00 price objective on shares of Rewalk Robotics in a report on Monday, November 6th. Piper Jaffray Companies restated a “buy” rating and set a $3.00 price objective on shares of Rewalk Robotics in a report on Sunday, January 7th. Oppenheimer set a $3.00 price objective on Rewalk Robotics and gave the stock a “buy” rating in a report on Tuesday, December 26th. Finally, Zacks Investment Research upgraded Rewalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a report on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Rewalk Robotics presently has an average rating of “Hold” and a consensus target price of $2.83.
Rewalk Robotics (NASDAQ:RWLK) opened at $1.15 on Friday. Rewalk Robotics has a 52 week low of $1.05 and a 52 week high of $3.20. The company has a current ratio of 2.02, a quick ratio of 1.65 and a debt-to-equity ratio of 7.46.
An institutional investor recently raised its position in Rewalk Robotics stock. Essex Investment Management Co. LLC raised its position in Rewalk Robotics Ltd (NASDAQ:RWLK) by 328.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 156,981 shares of the medical device company’s stock after buying an additional 120,362 shares during the period. Essex Investment Management Co. LLC owned approximately 0.72% of Rewalk Robotics worth $228,000 at the end of the most recent quarter. 3.24% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/04/analysts-expect-rewalk-robotics-ltd-rwlk-will-post-quarterly-sales-of-1-78-million.html.
Rewalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Get a free copy of the Zacks research report on Rewalk Robotics (RWLK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.